Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?

被引：0
|
作者：
Shing, Kit [1 ]
Kwok, Gerry [1 ]
Chiu, Joanne [1 ]
Cheung, Tan To [2 ]
Yau, Thomas [1 ]
机构：
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Peoples R China
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2020年 / 8卷 / 24期
关键词：
CHEMOTHERAPY;
D O I：
10.21037/atm-2020-130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Doxorubicin Plus Sorafenib in Treatment of Advanced Hepatocellular Carcinoma Reply
    Abou-Alfa, Ghassan
    Capanu, Marinela
    Saltz, Leonard
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (08): : 781 - 781
  • [2] Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial
    Abou-Alfa, Ghassan K.
    Johnson, Philip
    Knox, Jennifer J.
    Capanu, Marinela
    Davidenko, Irina
    Lacava, Juan
    Leung, Thomas
    Gansukh, Bolorsukh
    Saltz, Leonard B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (19): : 2154 - 2160
  • [3] Sorafenib in Hepatocellular Carcinoma: Separating the Hype From the Hope
    Kelley, Robin K.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 5845 - 5848
  • [4] Doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2011, 8 (2) : 61 - 61
  • [5] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
    Abou-Alfa, Ghassan K.
    Niedzwieski, Donna
    Knox, Jennifer J.
    Kaubisch, Andreas
    Posey, James
    Tan, Benjamin R.
    Kavan, Petr
    Goel, Rakesh
    Lammers, Philip Edward
    Bekaii-Saab, Tanios S.
    Tam, Vincent Channing
    Rajdev, Lakshmi
    Kelley, Robin Kate
    Siegel, Abby B.
    Balletti, Jennifer
    Harding, James J.
    Howard, Lawrence Schwartz
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
    Abou-Alfa, Ghassan K.
    Niedzwieski, Donna
    Knox, Jennifer J.
    Kaubisch, Andreas
    Posey, James
    Tan, Benjamin R.
    Kavan, Petr
    Goel, Rakesh
    Murray, John J.
    Bekaii-Saab, Tanios S.
    Tam, Vincent Channing
    Rajdev, Lakshmi
    Kelley, Robin Kate
    Siegel, Abby
    Balletti, Jennifer
    Harding, James J.
    Schwartz, Lawrence Howard
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
    Ghassan K. Abou-Alfa
    Stephan L. Chan
    Chia-Chi Lin
    E. Gabriela Chiorean
    Randall F. Holcombe
    Mary F. Mulcahy
    William D. Carter
    Kashyap Patel
    William R. Wilson
    Teresa J. Melink
    John C. Gutheil
    Chao-Jung Tsao
    Cancer Chemotherapy and Pharmacology, 2011, 68
  • [8] PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
    Abou-Alfa, Ghassan K.
    Chan, Stephan L.
    Lin, Chia-Chi
    Chiorean, E. Gabriela
    Holcombe, Randall F.
    Mulcahy, Mary F.
    Carter, William D.
    Patel, Kashyap
    Wilson, William R.
    Melink, Teresa J.
    Gutheil, John C.
    Tsao, Chao-Jung
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (02) : 539 - 545
  • [9] Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
    El Dika, Imane
    Capanu, Marinela
    Chou, Joanne F.
    Harding, James J.
    Ly, Michele
    Hrabovsky, Anna D.
    Do, Richard K. G.
    Shia, Jinru
    Millang, Brittanie
    Ma, Jennifer
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    CANCER MEDICINE, 2020, 9 (20): : 7453 - 7459
  • [10] Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma
    Abou Alfa, G. K.
    Johnson, P.
    Knox, J.
    Lacava, J.
    Leung, T.
    Mori, A.
    Leberre, M. A.
    Voliotis, D.
    Saltz, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 259 - 259
12345